HYL — Hyloris Pharmaceuticals SA Share News
0.000.00%
Last trade - 00:00- €108.08m
- €100.44m
- €7.21m
Brief: Hyloris Launches Equity Offering To Raise Around EUR 15 Million
Brief: Hyloris Pharmaceuticals NV ABB Bookrunner Says Offering Base Deal Size Of Approx. EUR 15M Of New Shares
Brief: Hyloris Pharmaceuticals End-Dec Cash, Cash Equivalents At EUR 50 mln
Brief: Hyloris Partners With Vaneltix For Interstitial Cystitis Pain Treatment
Brief: Hyloris Announces Earlier Than Expected PDUFA Date For Maxigesic® IV
Brief: Hyloris And Pleco Therapeutics Partner For Leukaemia And Cancer Treatment
Brief: Hyloris Announces Start Of Phase 2 In Miconazole-Domiphen Bromide Study
Hyloris up as FDA accepts new drug application to treat post-operative pain
Brief: Hyloris Announces FDA Acceptance Of New Drug Application For Maxigesic® IV In Post-Operative Pain
Brief: Hyloris Announces Approval Of Maxigesic IV In UK And Ireland
Brief: Hyloris Acquires Patented Technology For Acute Coronary Syndrome In The U.S.
Brief: Hyloris Acquires Global Rights To CRD-102 From Baker Institute
Brief: Hyloris Appoints Jean-Luc Vandebroek As Chief Financial Officer
Brief: Hyloris Announces Further Extension Of Maxigesic IV Footprint
Brief: Hyloris Pharmaceuticals Net Loss Widens To EUR 8.2 Mln
Brief: Hyloris Launches Non-Opioid Pain Treatment Maxigesic IV In Germany, Austria
Brief: Hyloris Renegotiates License Agreements With Alter Pharma Group
Brief: Hyloris: Extension Of Maxigesic IV Footprint Into South America
Brief: Hyloris: Partnership With Hikma For U.S. Commercialisation Of Maxigesic IV